Results 1 to 10 of about 863,344 (118)

CHI3L1 monoclonal antibody therapy mitigates cognitive impairment by inhibiting neuroinflammation through ERK and NF-κB pathway in Tg2576 mice [PDF]

Frontiers in Molecular Neuroscience
IntroductionAlzheimer’s disease (AD) is neurodegenerative disorder characterized by chronic inflammation in the brain. Chitinase-3-like 1 (CHI3L1), a secreted glycoprotein that is upregulated in a variety of diseases with chronic inflammation, represents
Hyeon Joo Ham, Seung Sik Park, Yong Sun Lee, Tae Hun Kim, Dong Ju Son, Ji-Hun Kim, Key-Hwan Lim, Hanseul Park, Hye Jin Lee, Jaesuk Yun, Sang-Bae Han, Min Ki Choi, Jin Tae Hong   +12 more
doaj   +2 more sources

Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC

Hepatology Communications, 2023
Background and Aims:. Efficacy of chimeric antigen receptor (CAR) T cells for treating solid tumors, including HCC, remains a challenge. Nanobodies are emerging building blocks of CAR T cells due to their small size and high expression. Membrane proximal
Aarti Kolluri, Dan Li, Nan Li, Zhijian Duan, Lewis R. Roberts, Mitchell Ho   +5 more
doaj   +1 more source

Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression

Journal of Experimental & Clinical Cancer Research, 2022
Background Peptide proteolysis-targeting chimeras (p-PROTACs) with advantages of high specificity and low toxicity have emerged as a powerful technology of targeted protein degradation for biomedical applications.
Kun Wang, Xiaoyong Dai, Albert Yu, Chunyan Feng, Kewei Liu, Laiqiang Huang   +5 more
doaj   +1 more source

Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China

Technology in Cancer Research & Treatment, 2023
In the era of precision medicine, with the deepening of the research on malignant tumor driving genes, clinical oncology has fully entered the era of targeted therapy.
Tao Li MD, Wen-Yu Yang BS, Ting-Ting Liu MD, Yao Li MD, Lu Liu MD, Xuan Zheng MD, Lei Zhao MD, Fan Zhang MD, Yi Hu MD   +8 more
doaj   +1 more source

Identification, Efficacy, and Stability Evaluation of Succinimide Modification With a High Abundance in the Framework Region of Golimumab

Frontiers in Chemistry, 2022
Succinimide (Asu) is the intermediate for asparagine deamidation in therapeutic proteins, and it can be readily hydrolyzed to form aspartate and iso-aspartate residues. Moreover, Asu plays an important role in the protein degradation pathways, asparagine
Tao Liu, Tao Liu, Tao Liu, Jin Xu, Jin Xu, Jin Xu, Jin Xu, Qingcheng Guo, Dapeng Zhang, Dapeng Zhang, Dapeng Zhang, Jun Li, Weizhu Qian, Weizhu Qian, Weizhu Qian, Huaizu Guo, Huaizu Guo, Huaizu Guo, Huaizu Guo, Xinli Zhou, Sheng Hou, Sheng Hou, Sheng Hou   +22 more
doaj   +1 more source

Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway

Advanced Science, 2023
Lysosome‐targeting chimeras (LYTACs) are an emerging therapeutic modality that effectively degrade cancer cell membranes and extracellular target proteins. In this study, a nanosphere‐based LYTAC degradation system is developed.
Kun Wang, Albert Yu, Kewei Liu, Chunyan Feng, Yibo Hou, Jiawei Chen, Shaohua Ma, Laiqiang Huang, Xiaoyong Dai   +8 more
doaj   +1 more source

Signaling Peptide SpoV Is Essential for Streptococcus pyogenes Virulence, and Prophylaxis with Anti-SpoV Decreases Disease Severity

Microorganisms, 2021
Streptococcal peptide of virulence (SpoV) is a Streptococcus pyogenes (group A streptococcus (GAS))-specific peptide that is important for GAS survival in murine blood, and the expression of the virulence factors streptolysin O (slo) and streptolysin S ...
Andrea L. Herrera, Michael S. Chaussee
doaj   +1 more source

The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma

Frontiers in Medicine, 2022
Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet ...
Tengfei Ma, Chad C. Wiggins, Breanna M. Kornatowski, Ra'ed S. Hailat, Andrew J. Clayburn, Winston L. Guo, Patrick W. Johnson, Jonathon W. Senefeld, Stephen A. Klassen, Sarah E. Baker, Katelyn A. Bruno, DeLisa Fairweather, R. Scott Wright, Rickey E. Carter, Chenxi Li, Michael J. Joyner, Nigel S. Paneth, Nigel S. Paneth   +17 more
doaj   +1 more source

The extracellular matrix protein fibulin-3/EFEMP1 promotes pleural mesothelioma growth by activation of PI3K/Akt signaling

Frontiers in Oncology, 2022
Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis and limited therapeutic options. The extracellular matrix protein fibulin-3/EFEMP1 accumulates in the pleural effusions of MPM patients and has been proposed as a prognostic ...
Arivazhagan Roshini, Chandra Goparaju, Somanath Kundu, Mohan S. Nandhu, Sharon L. Longo, John A. Longo, Joan Chou, Joan Chou, Frank A. Middleton, Harvey I. Pass, Mariano S. Viapiano, Mariano S. Viapiano   +11 more
doaj   +1 more source

Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series

Current Oncology, 2022
Patients with hematologic malignancies are at high risk of exacerbated condition and higher mortality from coronavirus disease 2019 (COVID-19). Bamlanivimab, casirivimab/imdevimab combination, and sotrovimab are monoclonal antibodies (mABs) that can ...
Göran Ramin Boeckel, Silke Dorothea Hölscher, Christin Bürger, Torid Jacob, Carolin Krekeler, Evgenii Shumilov, Christian Reicherts, Annalen Bleckmann, Georg Lenz, Richard Vollenberg, Phil-Robin Tepasse   +10 more
doaj   +1 more source